Agilent Crosslab was Agilent Technologies’s largest segment in fiscal 2025, bringing in $2.91B of $6.95B (42%).
| Business Segments | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Segment Total | — | — | — | — | |||||||||||||
| Life Sciences & Diagnostics Markets | — | $2.78B | $2.47B | $2.73B | |||||||||||||
| Life Sciences & Applied Markets | $3.63B | — | — | — | |||||||||||||
| Electronic Measurement | — | — | — | — | |||||||||||||
| Life Sciences & Diagnostics | — | — | — | — | |||||||||||||
| Agilent Crosslab | $1.45B | $2.66B | $2.75B | $2.91B | |||||||||||||
| Applied Markets | — | $1.40B | $1.30B | $1.31B | |||||||||||||
| Life Sciences | — | — | — | — | |||||||||||||
| Chemical Analysis | — | — | — | — | |||||||||||||
| Diagnostics & Genomics | $1.77B | — | — | — | |||||||||||||
| Total | $6.85B | $6.83B | $6.51B | $6.95B |
Agilent Technologies brought in $6.95B from its three segments in fiscal 2025, the year ended October 31, 2025. That was up 6.7% from $6.51B in fiscal 2024. Agilent Crosslab was the largest at $2.91B (41.9%), ahead of Life Sciences & Diagnostics Markets at $2.73B (39.2%) and Applied Markets at $1.31B (18.9%).
Compared with fiscal 2024, Life Sciences & Diagnostics Markets grew fastest, up 10.5% to $2.73B. Every segment above 2% of revenue grew.
Agilent Technologies began breaking out Life Sciences & Diagnostics Markets in fiscal 2023 and Applied Markets in fiscal 2023. Agilent Technologies stopped reporting Life Sciences & Applied Markets ($3.63B in fiscal 2022) and Diagnostics & Genomics ($1.77B in fiscal 2022) as separate segments.
Pharmaceutical & Biopharmaceutical Market was Agilent Technologies’s largest region in fiscal 2025, bringing in $2.51B of $6.95B (36%).
| End Markets | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Pharmaceutical & Biopharmaceutical Market | $2.52B | $2.43B | $2.24B | $2.51B | |||
| Chemical & Advanced Materials Market | $1.52B | $1.54B | $1.50B | $1.56B | |||
| Chemical & Energy Market | — | — | — | — | |||
| Diagnostics & Clinical Market | $963.00M | $966.00M | $964.00M | $1.03B | |||
| Environmental & Forensics Market | $656.00M | $662.00M | $650.00M | $674.00M | |||
| Food Market | $617.00M | $628.00M | $592.00M | $637.00M | |||
| Academia & Government Market | $576.00M | $601.00M | $567.00M | $540.00M | |||
| Total | $6.85B | $6.83B | $6.51B | $6.95B |
Agilent Technologies brought in $6.95B from its six regions in fiscal 2025, the year ended October 31, 2025. That was up 6.7% from $6.51B in fiscal 2024. Pharmaceutical & Biopharmaceutical Market was the largest at $2.51B (36.1%), ahead of Chemical & Advanced Materials Market at $1.56B (22.5%) and Diagnostics & Clinical Market at $1.03B (14.8%). The other three regions brought in $1.85B combined.
Compared with fiscal 2024, Pharmaceutical & Biopharmaceutical Market grew fastest, up 11.8% to $2.51B, while Academia & Government Market fell the most, down 4.8% to $540.00M. From fiscal 2022 to 2025, combined revenue from these regions grew from $6.85B to $6.95B, a compound annual growth rate of 0.5%. Pharmaceutical & Biopharmaceutical Market's share of the total fell from 36.7% to 36.1%.
Products was Agilent Technologies’s largest product and service line in fiscal 2025, bringing in $4.94B of $6.95B (71%).
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $5.19B | $5.05B | $4.67B | $4.94B | |||||||||
| Instrumentation | — | — | — | — | |||||||||
| Services & Other | $1.66B | $1.78B | $1.84B | $2.00B | |||||||||
| Analytical Lab Services | — | — | — | — | |||||||||
| Diagnostics & Genomics Solutions | — | — | — | — | |||||||||
| Analytical Lab Consumables | — | — | — | — | |||||||||
| Informatics & Other | — | — | — | — | |||||||||
| Total | $6.85B | $6.83B | $6.51B | $6.95B |
Agilent Technologies brought in $6.95B from its two product and service lines in fiscal 2025, the year ended October 31, 2025. That was up 6.7% from $6.51B in fiscal 2024. Products was the largest at $4.94B (71.2%), ahead of Services & Other at $2.00B (28.8%).
Compared with fiscal 2024, Services & Other grew 9.0% to $2.00B and Products grew 5.8% to $4.94B. From fiscal 2022 to 2025, combined revenue from these lines grew from $6.85B to $6.95B, a compound annual growth rate of 0.5%. Products' share of the total fell from 75.7% to 71.2%.
Agilent Technologies (A) reports its revenue by business segments, by end markets and by product and service. In fiscal 2025, Agilent Crosslab was its largest segment, bringing in $2.91B (41.9% of the total), followed by Life Sciences & Diagnostics Markets at $2.73B (39.2%).
Agilent Crosslab was Agilent Technologies' largest segment in fiscal 2025, bringing in $2.91B, or 41.9% of the $6.95B total across its three segments.
Pharmaceutical & Biopharmaceutical Market was Agilent Technologies' largest region in fiscal 2025, bringing in $2.51B, or 36.1% of the $6.95B total across its six regions.
Products was Agilent Technologies' largest product and service line in fiscal 2025, bringing in $4.94B, or 71.2% of the $6.95B total across its two product and service lines.
Among Agilent Technologies' segments that make up at least 2% of revenue, Life Sciences & Diagnostics Markets grew fastest in fiscal 2025, up 10.5% from $2.47B to $2.73B.
Every figure comes from Agilent Technologies' annual financial filings, as reported. Each line keeps the name Agilent Technologies gives it, and years follow its fiscal calendar.
Agilent Technologies' revenue by business segments goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.